Passage Bio Inc [PASG] stock is trading at $0.95, up 3.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PASG shares have gain 11.24% over the last week, with a monthly amount drifted -11.11%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Passage Bio Inc [NASDAQ: PASG] stock has seen the most recent analyst activity on March 08, 2022, when JP Morgan downgraded its rating to a Neutral. Previously, Goldman downgraded its rating to Neutral on January 19, 2022, and dropped its price target to $6. On July 01, 2021, Raymond James initiated with a Outperform rating and assigned a price target of $29 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $25 on June 15, 2021. Goldman upgraded its rating to a Buy and raised its price target to $30 on March 04, 2021. Guggenheim started tracking with a Buy rating for this stock on February 04, 2021, and assigned it a price target of $25. In a note dated January 25, 2021, Wedbush initiated an Outperform rating and provided a target price of $26 on this stock.
Passage Bio Inc [PASG] stock has fluctuated between $0.58 and $1.79 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Passage Bio Inc [NASDAQ: PASG] shares were valued at $0.95 at the most recent close of the market. An investor can expect a potential return of 531.58% based on the average PASG price forecast.
Analyzing the PASG fundamentals
Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -15.32%, Pretax Profit Margin comes in at -14.28%, and Net Profit Margin reading is -14.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.69 and Total Capital is -0.71. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8815 points at the first support level, and at 0.8119 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0007, and for the 2nd resistance point, it is at 1.0503.
Ratios To Look Out For
For context, Passage Bio Inc’s Current Ratio is 8.43. As well, the Quick Ratio is 8.43, while the Cash Ratio is 2.86.
Transactions by insiders
Recent insider trading involved Forman Mark S, CHIEF MEDICAL OFFICER, that happened on Feb 13 ’24 when 1638.0 shares were sold. SVP, INTERIM CFO, Borthwick Kathleen completed a deal on Feb 13 ’24 to sell 1470.0 shares. Meanwhile, Chief Medical Officer Forman Mark S sold 15813.0 shares on Jan 02 ’24.
